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Frontotemporal Dementia (FTD) is one of the most prevalent forms of early-onset dementia. 
However, the pathological mechanisms driving neuronal atrophy in FTD remain poorly 
understood. Here we identify a conserved role for the novel pro-apoptotic protein 
POSH/SH3RF1 in mediating neuropathology in 	 and mammalian models of 



associated FTD. Aberrant, AKT dependent, accumulation of POSH was 
observed throughout the nervous system of both 	 and mice expressing 



. Knockdown of POSH was shown to be neuroprotective and sufficient to 
alleviate aberrant neuronal morphology, behavioral deficits and premature-lethality in 
	 models, as well as dendritic collapse and cell death in 


expressing 
rat primary neurons. POSH knockdown also ameliorated elevated markers of JNK and 
apoptotic cascades in both 	 and mammalian models. This study provides the first 
characterization of POSH as a potential component of an FTD neuropathology, identifying a 
novel apoptotic pathway with relevance to the FTD spectrum. 
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Frontotemporal Dementia (FTD), a clinically, genetically and pathologically heterogeneous 
neurodegenerative disease, is a common form of early-onset dementia. FTD refers to a group 
of clinical syndromes associated with Frontotemporal lobar degeneration (FTLD), a 
progressive degeneration of the frontal and temporal lobes of the brain. The principal 
syndromes associated with FTLD include behavioral variant FTD (bvFTD), progressive non-
fluent aphasia, semantic dementia and FTD with Motor Neuron Disease (FTD-MND). 
bvFTD is the most prevalent, accounting for ~ 60% of all FTD cases. Perturbed regulation of 
apoptosis is a proposed mechanism underpinning neuronal death in FTD and has been 
observed in different FTD variants(1-7). A number of FTD loci are implicated in neuronal 
apoptosis (VCP, TBK1, GRN), however the cellular machinery driving the pro-apoptotic 
signal has yet to be determined(8, 9).   
 
Previously we established a 	 model of FTD associated with the bvFTD-disease 
causing mutation 


. 


causes a C-terminal truncation of 
the CHMP2B protein and failure of CHMP2B to dissociate from the endosomal sorting 
complex required for transport III complex(12, 13). Using this model we demonstrated 



 perturbs normal endosomal and autophagic trafficking  . Neuronal 
loss through phagocytic clearance of apoptotic neurons has been observed in

 
models(14), however the mechanisms driving this process are not fully established. 
Previously we found the pro-apoptotic JNK scaffold Plenty of SH3’s (POSH/SH3RF1) is 
activated in 	 mutants(7), dominant enhancers of 


. We now show POSH 
accumulates in the nervous system and mediates toxicity in 	 and mammalian 
models of 


. 
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POSH forms a scaffold for a multi-protein complex involved in JNK and NF-κB dependent 
apoptosis(15-17). This complex assembles following apoptotic stimuli and stabilises through 
association with JNK components(18-22). This self-amplifying feedback loop leads to JNK-
dependent apoptosis and cell death(22). POSH overexpression induces neuronal apoptosis 
while knockdown conveys neuroprotection against ischemia(16, 23, 24). AKT inhibits POSH 
dependent apoptosis by promoting disassembly of the pro-apoptotic POSH-JNK complex(18-
20). 

Using our 	 model of 


 dominant screens were performed, identifying 
loci modifying 

 
toxicity(7, 10, 11). This identified the pro-survival gene AKT 
as a potent modifier of 


 toxicity. Having shown accumulation of POSH to 
mediate neuronal dysfunction in 	 mutants(7), another dominant modifier of 
CHM2B
Intron5
, this study looked to elucidate a role for POSH as a component of 
neuropathological and pro-apoptotic cascades in FTD. Using 	, primary 
mammalian neurons and neuronal tissue from 

 
expressing mice we 
demonstrate POSH to be a conserved component of pathology in 


 !We 
show POSH accumulates in neurons and drives unregulated synaptic growth, behavioral 
dysfunction and early-lethality in flies. POSH knockdown ameliorated dendritic collapse in 
primary mammalian neurons expressing CHMP2B
Intron5
. In keeping with the pro-apoptotic 
function of POSH we demonstrate expression of 


 results in elevated JNK and 
apoptotic markers, both of which can be alleviated by POSH knockdown. This study 
implicates POSH as an important component of toxicity in 

 
FTD, defining a 
novel pathway potentially mediating toxicity and neuronal survival in FTD. 


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

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 

Expression of the disease-causing 


 mutant transgene in the 	 eye 
elicits a perturbed eye phenotype, described previously(7, 10, 11). This phenotype allowed us 
to screen ~ 80% of the 	 genome for dominant modifiers of 

 
toxicity(7, 10, 11). Here we identify "#$ as a dominant enhancer of toxicity, with "#$ loss-
of-function alleles "#$
%&
 and "#$
'
 and AKT knockdown, via RNAi, potentiating the 



 eye phenotype (Fig. 1a-b). The kinase-dead "#$ allele "#$

 showed the most 
significant enhancement of the eye phenotype  (Fig. 1a-b)(25). 

We previously demonstrated pan-neuronal expression of 


 results in 
unregulated synaptic overgrowth at the 	 larval neuromuscular junction (NMJ)!
We therefore employed this model to establish whether expression of AKT could alleviate 
neuronal aberrations in larvae pan-neuronally (()-Gal4) expressing 


. 
Expression of AKT or constitutively active myristoylated AKT (myrAKT) was sufficient to 
alleviate synaptic overgrowth, reducing both elevated synaptic bouton number and NMJ 
length (Fig. 1c-e). Co-expression of UAS-mCD8-GFP with 


 showed no 
variance to 


 expression alone, indicating rescues were not the result of titrating 
Gal4. To provide a functional, behavioral readout of NMJ activity larval locomotor assays 
were employed. 

 
expressing larvae displayed significantly reduced larval 
crawling velocity, compared to wild-types or controls (Fig. 1f). Co-expression of AKT or 
myrAKT with 


 was sufficient to partially rescue locomotor deficits, with the 
myrAKT providing the most significant rescue (Fig. 1f). 
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
AKT exhibits anti-apoptotic activity in neurons through direct interaction and 
phosphorylation of POSH(18). Previously we demonstrated POSH accumulation in the 
nervous system of larvae mutant for 	, a dominant modifier of 


. Rab8 
also interacts with TBK1, Optineurin and C9orf72, known loci causing FTD and MND(26-
28). We therefore asked whether POSH accumulation was also observed in the nervous 
system of larvae expressing 


, in a manner phenocopying 	 mutants. Pan-
neuronal expression of 


 resulted in aberrant accumulation of POSH in distinct 
puncta throughout the larval ventral nerve cord (VNC) (fig. 2a). Puncta were most frequently 
observed within the neuropil, mimicking 	 mutants, which show POSH accumulations 
throughout their axons. Quantification revealed a significant increase in POSH accumulations 
in the VNC of 


 expressing animals, compared to wild-type (Fig. 2b). Having 
observed pan-neuronal expression of 


 perturbs synaptic structure and function 
at the 	 larval NMJ (Fig. 1c-f) we also asked whether 


expression 
within motor neurons, using the OK6-Gal4 Driver, induced aberrant accumulation of POSH. 
Motor neuronal expression of 


was sufficient to

induce aberrant accumulation 
of POSH puncta throughout the neuropil region of the VNC (Fig. 2c). 
 
POSH is a substrate of AKT * and in cell culture, with phosphorylation of POSH by 
AKT negatively regulating assembly of the pro-apoptotic POSH complex(18). We therefore 
looked to ascertain whether this interaction occurred  ** in the 	 nervous 
system and whether inhibition of AKT kinase function affected POSH accumulation. The 
	 "#$
 
mutant allele is characterized by a point mutation leading to a single amino-
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acid change (F327I) within a highly conserved region of the kinase catalytic core 
domain(25). This mutation results in a complete loss of kinase activity and is considered a 
kinase-dead allele. POSH was shown to accumulate throughout the larval VNC of "#$

 
kinase-dead flies in a manner phenocopying 


(fig. 2d). No significant 
accumulation of POSH was observed in wild-type animals. Immunoblotting using the anti-
Phospho-(Ser/Thr) Akt Substrate Antibody, which preferentially recognizes peptides 
phosphorylated by AKT, following immunoprecipitation of POSH from 	lysates
confirmed POSH to be a direct substrate of AKT **(18) (supplementary fig. 1a). 
 
Having observed POSH accumulations in the nervous system of "#$

 kinase dead flies (Fig. 
2d) and demonstrated expression of AKT to be sufficient to rescue synaptic overgrowth at the 
	 larval NMJ in 


 expressing animals (Fig. 1c-e), we looked to 
ascertain whether AKT expression could alleviate aberrant accumulation of POSH in the 
nervous system of 


 flies. Expression of AKT was sufficient to reduce the 
number of distinct POSH puncta observed within the VNC and resulted in a re-distribution of 
POSH to a more diffuse cytosolic localization (Fig. 2e-f). This was supported by our 
observation that overexpression of myrAKT was able to rescue reduced phosphorylation of 
POSH observed in lysates extracted from the VNC of 


 larvae (Supplementary 
Fig.1b). 

!2.!	3
	

 !

Having confirmed that POSH is a direct substrate of AKT and shown that AKT expression is 
sufficient to alleviate synaptic perturbations and aberrant localization of POSH in 



 expressing larvae, we asked whether POSH played a critical role in driving 
pathological pathways in 


 expressing animals. Using the 	 larval 
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NMJ as a model synapse we demonstrate knockdown of POSH via RNAi or using the 
previously characterized hypomorphic allele +(
%
 (7, 29) was sufficient to alleviate all 
aspects of synaptic overgrowth observed in 

 
expressing larvae, including 
increased synaptic bouton number and synapse length (Fig. 3a-c). Knockdown of POSH also 
alleviated impaired larval crawling in 


 expressing larvae (Fig. 3d).    
 
In addition to neuroanatomical perturbations at the 	 larval NMJ pan-neuronal 
expression of 

 
results in a 100% pharate (adult pupal) lethal phenotype. In 
order to ascertain whether inhibition of POSH could reduce the penetrance of this lethal 
phase, survival assays were performed. Experimental crosses were designed to give a 50:50 
ratio of progeny either pan-neuronally expressing 


 or siblings not expressing 



 but carrying an identifiable marker (
)+, balancer chromosome with curly 
wings). The effect of reducing POSH exp ession, using both heterozygous and homozygous 
POSH mutants, on survival was then assessed in these backgrounds by scoring the number of 
flies with normal or curly wings eclosing as adults. A wild-type cross giving a 50:50 ratio of 
straight:curly winged flies was used as a baseline control. Pan-neuronal expression of 


 
resulted in a 100% lethal phenotype, with all eclosing offspring carrying the 

)+ balancer (Fig 3e). In contrast, homozygous +(+(
%,%
mutants pan-neuronally 
expressing 


 showed reduced lethality, with 40% of eclosing flies expressing 
the 


transgene (Fig 3e). 

1! 	1"1!   !)    '!3 ! ""!

	

# 

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Having observed aberrant accumulation of POSH within the nervous system of flies 
expressing 


 we asked whether this phenotype was conserved in mammalian 
CHMP2B
Intron5
 models. We therefore employed our previously established 


 
mouse model(30). POSH accumulation was observed in β3-tubulin positive neurons within 
the frontal cortex of 12-month old mice expressing 


 but not aged matched 


-.)  
expressing controls
 
(Fig.4). Accumulations were specific to the cell body 
and neuronal processes. Quantification of the relative fluorescence abundance of POSH 
within β3-tubulin positive neurons showed a significant increase in 


 
expressing mice, compared to 

-.) 
controls. β3-tubulin expression showed no 
significant variance to wild-type. 
 
Previously we demonstrated mammalian neurons transfected with 


 show 
dendritic collapse prior to death(13). Similar phenotypes are observed via knockdown of 

(31). In order to ascertain whether POSH plays a functional role in 


 
toxicity in mammalian neurons, we asked whether knockdown of POSH via shRNA could 
alleviate dendritic collapse and convey neuroprotection (Fig.5). Neurons transfected with 



 showed a significant dendritic collapse phenotype compared to those 
transfected with wild-type 
. Sholl analysis revealed 

 
transfected 
neurons show reduced complexity of the dendritic arbor, with a significant decrease in the 
number of cumulative intersections observed compared to neurons transfected CHMP2B
Wild-
type
 (Fig. 5a-b). 

 
transfected neurons also showed a significant reduction in the 
length of the longest neuronal process (Fig. 5a&c, 56% reduction), the maximum number of 
intersections at any given distance from the cell body (Fig. 5a&d, 50% reduction) and the 
total arbor size (Fig. 5a&e, 66% reduction). The total perimeter of the cell body showed no 
variance between neurons transfected with either 


 or 

-.) 
. Co-
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transfection of +( shRNA’s was sufficient to alleviate all aspects of perturbed dendritic 
morphology associated with expression of 


 (Fig.5). 

!2.!	343	

'0!
	

$
 
Previous studies have identified POSH as a pro-apoptotic JNK scaffold(15-17). 
Overexpression of POSH has been shown to induce neuronal apoptosis while knockdown 
conveys neuroprotection against ischemia(16, 23, 24). Having observed neuroprotection via 
knockdown of POSH in both 	 and mammalian models of 


 FTD, we 
asked whether expression of 

 
resulted in elevated JNK and apoptotic activity in 
these models. 
 
Pan-neuronal expression of 


 resulted in an increase in TUNEL staining 
observed in the 	 larval VNC (Fig. 6a), coupled with a significant increase in the 
expression of cleaved Death Caspase 1 (Dcp-1) (Fig. 6b-c), the activated 	 effector 
caspase(32). Immunoblotting revealed a 1.7 fold increase in cleaved Dcp-1 in the larval 
VNC, compared to wild-type (Fig. 6b) while immunofluorescence quantification of cleaved 
Dcp-1 specifically within elav positive neurons in the VNC revealed a 1.5 fold increase (Fig. 
6c). Reduction of POSH abundance in flies expressing 

 
using the hypomorphic 
POSH
74 
allele was sufficient to rescue cleaved Dcp-1 levels back to wild-type levels (Fig. 6b-
c). Cleaved caspase 3 was also shown to be elevated in rat endothelial cells transfected with 



, but not 

-.) 
, supporting observations made in 	 (Fig. 
6d). Inhibition of apoptosis using the deficiency allele Df(3L)H99, which has previously been 
shown to completely block apoptosis by deleting three essential pro-apoptotic genes(33), 
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acted to partially alleviate the 


 eye phenotype, reducing the severity of the 
black spot phenotype observed  (Fig. 6e&f). 

Having observed increased apoptotic activity in both 	 and mammalian models of 



 FTD, and taking into account the role of POSH as a pro-apoptotic JNK 
scaffold, we asked whether these models showed elevated JNK signalling and whether this 
could be alleviated by inhibition of POSH. Puckered (puc), a negative regulator of JNK 
transcriptionally activated by the JNK signaling pathway, has previously been shown to 
provide a reliable transcriptional readout of JNK activity(34, 35). Using a /0-lacZ 
reporter(34) we demonstrate a significant increase in JNK activity within the nervous system 
of 


 expressing larvae (Fig. 6g), supporting our previous observations(7). 
Inhibition of POSH was sufficient to alleviate elevated levels of /0. A significant increase in 
phospho-JNK was also observed in lysates extracted from the cortex of 12-month-old 



 expressing mice, compared to aged matched CHMP2B
Wild-type
 expressing 
controls (Fig. 6h&i). 

#1!
As part of an ongoing, functional screen to identify signaling mechanisms driving pathology 
in FTD we identified AKT as a potent modifier of 


 toxicity. Expression of 


 
lead to aberrant accumulation of POSH, which is known to be negatively 
regulated by AKT(18, 20), in the nervous system of both 	 and mammalian 
models. Having previously implicated POSH as a potential regulator of neuronal 
dysfunction(7) this study now defines, for the first time, the function of this novel regulator 
of apoptosis in an FTD model.  
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	#
AKT has been implicated in the regulation of neuronal growth and survival as well as 
conveying neuroprotection in response to neuronal insults(36-39). It has been identified as a 
potential therapeutic target for neuroprotective compounds in response to ischemia and 
neurotoxic apoptosis(40).  Perturbations to AKT function have been implicated in a number 
of neurodegenerative disorders including Alzheimer’s Disease and FTD(41-44). It has also 
been show to directly interact with a number of proteins associated with FTD disease causing 
loci, including TBK1 and VCP(45-47). In this study, we identified the single 	 
isoform of AKT, to be a potent modifier of 


 toxicity. "#$ loss-of-function 
mutants were shown to significantly enhance the eye phenotype associated with 


 
expression, revealing heterozygous mutations of AKT to be dominant 
enhancers of 


 toxicity. The most significant enhancement to the eye phenotype 
was shown by the "#$
 
allele, an endogenous kinase-dead allele(25). This observation 
suggests an important functional role for AKT kinase activity in preventing neurotoxicity 
associated with the 


 mutation. This is supported by the ability of both AKT 
and the constitutively active myristoylated AKT to rescue aberrant synaptic growth at the 
	 larval NMJ, as well as impaired locomotor velocity. We also substantiate 
previous findings that POSH is a direct substrate of AKT and show that POSH aberrantly 
accumulates in the CNS of AKT kinase-dead flies. Despite this we did not observe changes 
in either AKT or pAKT levels in 


models (data not shown). This suggests 
POSH accumulation in 


 does not occur as a result of perturbed pro-survival 
AKT function, but more likely in response to endogenous pro-apoptotic stimuli promoting 
assembly of the active POSH-complex. Activation of the pro-survival AKT pathway, 
however, is sufficient to alleviate POSH mediated toxicity, most likely through its known 
role as a negative regulator of POSH. This may therefore represent a pathway for therapeutic 
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intervention. Similarly, disruption to AKT kinase function may potentiate disease severity by 
reducing negative regulation of the POSH signaling complex.  
Additionally, we have demonstrated that reducing +( expression alleviates synaptic 
overgrowth both in 

 
expressing flies and, previously, in 	 mutants(7). 
Collectively this data reveals POSH as a novel candidate potentially acting downstream of 
AKT to modulate synaptic structural homeostasis. Given the known function of POSH as a 
JNK scaffold and the well-established role of the JNK-activator protein 1 (AP-1) pathway in 
regulating synaptic outgrowth at the 	 NMJ, POSH represents a promising 
candidate linking AKT to JNK-dependent regulation of NMJ morphology in an antagonistic 
manner. Given the conservation of AKT and JNK signaling pathways in neuronal growth and 
plasticity across species, observations made at the 	 larval NMJ may be directly 
translatable to a mammalian system and in the regulation of neuronal homeostasis in 
neuropathology(48, 49).  
 
 
1!* 	
 
Scaffolding proteins are post-translationally modified to modulate their activation state. AKT 
is as a negative regulator of the pro-apoptotic POSH-JNK signalling complex in the 
mammalian nervous system and in cell culture(18, 20). Negative regulation of this complex 
occurs through phosphorylation of POSH and its interacting partners(18-20). Direct 
phosphorylation of POSH by AKT, however, has previously only been shown * or in 
cell culture(18). Here we provide evidence that POSH is an AKT substrate in the 	 
nervous system and that inhibition of AKT kinase function leads to aberrant POSH 
accumulation. The observation that AKT expression alleviates POSH accumulation and 
toxicity in the nervous system of 

 
expressing flies also provides context for this 
pathway in FTD. Identification of this pathway in the regulation of neuronal growth and 
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function in FTD model identifies the POSH signalling complex as a novel target mediating 
neuronal dysfunction and neurodegeneration in FTD.  

0!*!    1
3 ! 
 ! ""!  

	

#
POSH has been implicated in the development and maintenance of the nervous system, 
including neuronal migration and axon outgrowth(50-52). POSH knockdown conveys 
neuroprotection in response to neuronal insults, suggesting an important role for POSH in the 
regulation and survival of neurons(16, 24). For example, knockdown of POSH is 
neuroprotective in response to cerebral ischemia and growth factor withdrawal(16, 24). 
Conversely, overexpression of POSH induces caspase-dependent cell death(53). AKT is also 
implicated in neuroprotection in response to ischemia and growth factor withdrawal, 
supporting a conserved mechanism in which modulation of POSH by AKT promotes 
neuroprotection in response to neuronal insults(36-39). Here we provide evidence that POSH 
knockdown is sufficient to alleviate neuronal perturbations in both 	 and 
mammalian models of FTD associated with the disease-causing 


 mutation. 
POSH knockdown in 	 pan-neuronally expressing 

 
completely 
alleviated unregulated neuronal growth at the larval NMJ. Importantly POSH knockdown had 
no effect upon neuroanatomy in wild-type larvae suggesting a role for POSH in pathological 
neuronal dysfunction, rather than as a mediator of neuronal growth. POSH knockdown was 
also sufficient to ameliorate perturbed larval crawling and early-lethality observed in 


 
flies, suggesting a pathological role for POSH leading to premature lethality 
in 	. The observation that POSH knockdown ameliorated all aspects of the 
dendritic collapse phenotype observed in primary neurons transfected with 


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provides functional evidence for a conserved role of POSH in the transduction of neurotoxic 
pathways in both 	 and mammalian models of disease. 




!#
Premature apoptosis has been observed as an early event occurring in different FTD 
variants(1) and a number of FTD causing loci are implicated in neuronal apoptosis (VCP, 
TBK1, GRN)(8, 9). Activation of microglia has also been shown to promote clearance of 
apoptotic neurons observed in the brains of 18-month old 


 mice, but not aged 
matched 

-.)  
or non-transgenic controls, indicating aberrant neuronal apoptosis 
may be driving cell-loss in 


-associated FTD(14). Mutations in 
 have 
also been suggested to pre-dispose neurons to apoptosis(54). However, our understanding of 
whether apoptosis is driving cell death in FTD and the molecular machinery regulating this 
process remains poorly understood. Our observation that the pro-apoptotic JNK scaffold 
POSH aberrantly accumulates in both 	 and mammalian models of 


 
FTD and that POSH knockdown alleviates aberrant neuronal phenotypes identifies it as a 
potentially novel pro-apoptotic factor in FTD pathology. 
 
POSH was initially identified in the regulation of JNK and NF-κB dependent apoptosis(15). 
POSH overexpression promotes caspase-dependent cell death, while knockdown promotes 
neuroprotection following neuronal insult(16, 23, 24). Ablation of SH3RF2, a negative 
regulator of POSH, leads to enhanced caspase-8 activity(55). Conversely expression of 
SH3RF2 prevents apoptosis and promotes neuronal cell survival through inhibition of 
POSH(21, 55). The pro-apoptotic function of Nix/BNIP3L, has also been shown to be 
dependent upon interaction with POSH(56) .  However, to date, POSH remains poorly 
studied and its role in neurodegenerative diseases remains unknown. This study is the first, to 
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our knowledge, providing a functional context for POSH in a neurodegenerative disorder. We 
provide evidence that inhibition of POSH alleviates elevated caspase activity in both 
	 and mammalian 


-induced FTD models. We also reveal inhibition 
of apoptosis using the 1'233 deficiency locus, which ablates 3 essential apoptotic genes 
and reduces 


 toxicity as a heterozygote. However, it is important to note that 
the 1'233	  does not completely alleviate the eye phenotype, suggesting a potential 
role for alternative pathways in 


 toxicity. These may include non-canonical 
cell death pathways as well as autophagic pathways, which are known to be perturbed in 



 models. Interestingly the 	 effector caspase Dcp-1 has also been 
implicated in autophagic flux(57). This may represent a broader link to other mechanisms of 
cell death and autophagic disruption in FTD. 

0"
!#
In this study we provide evidence for a functional, novel, role for the pro-apoptotic JNK 
scaffold POSH in mediating neuropathology in 	 and mammalian models of FTD 
associated with the disease-causing mutation 


. Aberrant apoptosis has been 
implicated as a potential mechanism driving neuronal cell death and gliosis in a number of 
FTD variants.  The observation that POSH is perturbed in 


models therefore 
raises the question of whether this novel apoptotic-regulator has a functional role in other 
variants of the disease, or even more broadly in neurodegenerative diseases. Future 
investigation into the role of POSH in FTD and other neurodegenerative diseases, as well as 
whether aberrant POSH accumulation is conserved in patients, will be critical to elucidate the 
role of POSH neurodegeneration. Further investigation into novel interacting partners of 
POSH in both healthy and diseased neurons may also help to delineate mechanisms 
regulating POSH and its downstream effects on neurodegeneration.  
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These observations provide the first characterization of POSH as a potential component of 
neuropathological cascades in FTD. It also reveals POSH as a novel target for further 
investigation and potential therapeutic intervention. Aberrant accumulation of POSH may 
also represent a biomarker of the disease though further investigation will be required to 
determine this. 
 

!
	  
Stocks and Husbandry: 
	 were raised on standard cornmeal-yeast-sucrose medium at 25°C on a 12h 
light:dark cycle. CHMP2B
Intron5
 flies were described previously (7, 10). All other stocks were 
obtained from the following sources: POSH
74
 (Toshiro Aigaki, Tokyo Metropolitan 
University, Japan) (29), AKT
1
 (Clive Wilson, University of Oxford, UK) (25), OK6-Gal4 
(Cahir O’Kane, University of Cambridge, UK), UAS-myrAKT, UAS-mCD8-GFP, AKT
04226
, 
AKT
3
, UAS-AKT-RNAi (BL #33615), UAS-mCherry-POSH, UAS-POSH-RNAi (BL 
#64569), Df(3L)H99, Puc-LacZ, GMR-Gal4, nSyb-Gal4, Canton S, w
1118
, (Bloomington 
Stock Center). UAS-AKT (FlyORF, Zurich, Switzerland). All wild-types were an outcross of 
Canton S to w
1118
. 
 
Genetic interaction experiments and quantification of the 


 eye phenotype was 
performed as described previously (7). Eyes were imaged using an AxioCam ERc 5s camera 
(Carl Zeiss) mounted on a Stemi 2000-C stereo microscope (Carl Zeiss).  
 
Immunohistochemistry: 
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	 Immunohistochemistry was performed as described previously(7).  Primary 
antibodies used were: Cleaved Dcp-1 (Cell Signaling Technology, 9578, 1:100), HRP-Cy3 
(Jackson scientific, Stratech), Synaptotagmin (1:2000)(7), β-galactosidase (1:1,000; MP 
Biologicals 0855976) and anti-elav (1:50, DSHB 9F8A9). All primary antibodies were 
incubated overnight at 4°C in PBS-T (0.1% Triton X-100), all secondary antibodies were 
incubated for 1h at room temp (~21°C) in PBS-T. Terminal Deoxynucleotidyl Transferase 
(TdT)-Mediated dUTP Nick-End Labeling (TUNEL) staining was performed using TMR-red 
detection kit (Roche, 12 156 792 910). 
 
Imaging and Quantification: 
Quantification of synaptic bouton number at the 	 third instar larval Neuromuscular 
Junction (NMJ) was performed as described previously (7). Confocal microscopy was 
performed using a Zeiss LSM 880 on an Axio Observer.Z1 invert confocal microscope 
(Zeiss). Z-stacked projections of NMJ’s and VNCs were obtained using a Plan Neofluar 
40x/0.75 NA oil objective. NMJ lengths were measured from stacked NMJ images using the 
NeuronJ plugin for ImageJ (National Institutes of Health) as described previously (7). 
Corrected total cell fluorescence quantification was performed as described previously using 
ImageJ (7). Neurons were identified in the 	 larval VNC using anti-elav.  
 
Larval Locomotor Assay: 
Female third instar wandering larvae of the appropriate genotype were selected and 
transferred into HL3 (70 mM NaCl, 5 mM KCl, 1 mM CaCl2.2H2O, 10 mM NaHCO3, 5 mM 
trehalose, 115 mM sucrose and 5 mM BES in dH2O) to wash off any debris. 2-3 larvae were 
transferred onto the center of a 90mm diameter petri-dish containing a thin layer of 1% agar 
and left to acclimatise. The petri dish was placed upon a black surface and imaged from 
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above using a digital webcam (Creative labs, UK). Experiments were performed at 25°C. 
Upon initiation of crawling larvae were recorded for 120 sec. (0.2 frames sec-1) using 
VirtualDub software. Images were analysed using imageJ.  Briefly videos were batch 
thresholded and a custom macro used to track, via the MTrack2 plugin, and plot the larval 
positions. This data was then used to determine the mean larval velocity. 
 
Mouse 
Ex Vivo Histology: 
Brains were isolated from 12 month aged CHMP2B
Wild-type
 and CHMP2B
Intron5 
expressing 
mice, described previously (30), and fixed in 4% formalin for 24 hours. Tissue was 
embedded in paraffin blocks and 5 m sagittal sections taken. Sections were deparaffinised 
by heating at 55°C for 10 mins followed by further xylene deparaffinisaton and rehydrated in 
a graded series of ethanol. Heat mediated antigen retrieval was performed in sodium citrate 
buffer (10 mM Sodium citrate, 0.05% Tween 20, pH 6.0, 95°C, 10 mins.) followed by 
Retrievagen (pH 6.0, 95°C, 10 mins. BD Biosciences). Samples were blocked in 5% Goat 
Serum (TBST 0.025%, 1h room temp.) followed by endogenous mouse IgG blocking 
(AffiniPure Fab Fragment Goat Anti-Mouse IgG (H+L), Jackson immune research, stratech). 
Samples were incubated in primary antibodies (POSH (1:100, Proteintech, 14649-1-AP) and 
β3 Tubulin (1:500, Sigma T-8660) 1% BSA, TBST 0.025%, overnight, 4°C) followed by 
secondary antibodies (goat anti-mouse FITC, goat anti-rabbit Cy3, 1h, room temperature, 
Jackson scientific, stratech). Samples were mounted in Vectashield mounting media + DAPI 
(H-1200, Vector labs) and analyzed using a Zeiss LSM 880 confocal (Plan Neofluar 40x/0.75 
NA oil objective). Relative abundance of POSH within mouse cortical neurons was 
determined via corrected total cell fluorescence (CTCF) using ImageJ. Relative fluorescence 
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intensity of POSH was normalized against relative fluorescence intensity of β3-Tubulin. 3 – 
5 cortical neurons per animal, 3 animals per genotype were analysed.   
 
Cell Culture 
"	4/5
Timed mated female Wistar rats (Charles River UK) (RRID:RGD_737929) were maintained 
in accordance with the ARRIVE guidelines and the UK Animals (Scientific Procedures) Act 
(1986). Hippocampi were dissected from postnatal day 1-4 (P1-4) rat pups. Animals were 
euthanised using pentobarbital injection followed by cervical dislocation, according to Home 
Office guidelines. Hippocampal cell suspensions were obtained as previously described 
(Potter, 1989) and cultured in Neurobasal medium (21103049, Thermo Scientific) 
supplemented with B27 (50x, 17504044, Thermo Scientific), Glucose (35mM final 
concentration, A2494001, Thermo Scientific), L-glutamine (1mM, 25030032, Thermo 
Scientific), Foetal Calf Serum (5%, Mycoplex, PAA), Penicillin (100u/ml) and Steptomycin 
(100µg/ml, 15140122, Thermo Scientific) and maintained at 37°C in 5% CO2.  
Neurons were transfected at 12 days  * (DIV) with Lipofectamine 2000 (11668019, 
Thermo Scientific) with either FLAG-tagged 

6.) 
 or 


, described 
previously (13), and with POSH ShRNA 1+2 or Scrambled ShRNA’s (52) (supplementary 
Fig. 1c).  After 2/3 days, cells were fixed or lysed for biochemical experiments. GPNT’s 
(Sigma) were cultured in Ham’s F-10 (Lonza, BE12-618F) with L-Glutamine supplemented 
with basic fibroblast growth factor (FGF, 2ng/ml, Sigma F3685), heparin (80µg/ml, Sigma 
H3149) and Foetal Calf Serum (10%). Cells were plated in 35mm dishes and at ~70% 
confluency transfected with either 20µg CHMP2B
Wild-type
 or CHMP2B
Intron5
. After 3 DIV, 
cells were lysed for western blotting. Culture media was routinely screened for mycoplasma 
contamination.  
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Immunocytochemistry: 
Cells were washed with phosphate buffered saline (PBS) and fixed for 30 min at room 
temperature with 4% paraformaldehyde (containing 4% sucrose) (Sigma) PBS. Cells were 
permeabilized in 0.5% NP40 in PBS for 5 minutes at room temperature. Primary antibodies 
used were as follows: anti-FLAG (Sigma M2 clone, 1:1000), anti-GFP (eBioscience, 14-
6758-81, 1:1000). dsRed was detected using FluoTag-X4, ATTO 542 (1:500, Synaptic 
Systems). Primary antibodies were incubated overnight at 4°C. Corresponding Alexafluor 
secondary antibodies (1:500, Thermo Scientific) were incubated for 1 hour at room 
temperature before mounting with Fluoromount (Sigma). 
00)		4 "	)5 
Images were collected on an inverted Zeiss microscope (880) with 20x or 63x Plan Neofluar 
objectives using Zeiss filter sets for DAPI and Alexa 488/546/633. Images were taken at an 
aspect ratio of 2048x2048. Images of neurons were traced using the NeuronJ plugin in 
ImageJ (1.6.0). Individual traces were saved, thresholded and sholl analysis was conducted 
using the Sholl plugin.  
 
Biochemistry 
Western Blotting: 
7 brains, per genotype, were dissected from third instar wandering larvae and boiled in 20l 
of 2x laemmli loading buffer. Cells were lysed in RIPA containing phosSTOP phosphatase 
inhibitors (Roche) and cOmplete EDTA free protease inhibitors (Roche). Cortical lysates 
were extracted from mouse brain as described previously (30). After boiling in loading buffer 
samples were run on a 4–20% Mini-PROTEAN
®
 TGX™ Precast Protein Gels (Biorad) prior 
to transfer onto standard PVDF membrane. Antibodies used for immunoblotting wereGuinea 
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Pig Anti-POSH (193, 1:5000), anti-Phospho-(Ser/Thr) Akt Substrate (Cell signaling 
Technology, 9611, 1:1000), anti-Cleaved Dcp-1 (Cell Signaling Technology 9578, 1:1000), 
anti-β-Actin (Proteintech, 60008-1-Ig (7D2C10), 1:180 000), anti-Cleaved Caspase 3 (CC3) 
(1:200, Cell Signaling Technology 9661), anti-GAPDH (Merck, MAB374 (6C5), 1:10,000), 
anti-pJNK (Promega Active JNK, pTPpY, 1:5000) and anti-Pan-JNK (Cell Signaling 
Technology 9252 1:1000). Secondary antibodies were Peroxidase-conjugated AffiniPure 
Goat Anti-Guinea Pig, anti-rabbit and anti-mouse IgG (H+L) (Jackson Scientific, 106-035-
003, 111-035-144 and 115-035-003, 1:10 000). For immunoblotting following 
immunoprecipitation secondary antibodies were Peroxidase-conjugated protein-G (Merck 
Millipore 18-161, 1:10 000). POSH antibodies were produced from full length GST-tagged 
	 POSH, generated from POSH cDNA (LD45365, Berkeley Drosophila Genome 
Project Gold Collection) and injected into Rabbit or Guinea Pig (eurogentec, 87-day 
immunization). Phospho mobility shift gels were performed by addition of Phos-tag 
acrylamide (AAL-107, Wako laboratory chemicals) to standard acrylamide gels as per the 
manufacturer’s instructions.  

Immunoprecipitation:  
For immunoprecipitation protein was extracted from 	 in RIPA containing 
phosSTOP phosphatase inhibitors (Roche) and cOmplete EDTA free protease inhibitors 
(Roche). Lysates were incubated at a concentration of 1mg/ml with Rabbit Anti-POSH (429, 
4°C, overnight)) followed by incubation with protein A-agarose beads (Sigma, P2545, 4°C, 4 
hours). Following incubation Protein A-agarose beads were collected using a Spin-X tube 
filter (Corning, Costar, 0.45m), washed and the sample eluted in 2x laemmli. Western 
blotting was performed as described above.  
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Statistics: 
Statistical analysis was performed using either SPSS Statistics (IBM, Version 24) or 
GraphPad Prism (6.01). Data are presented as mean values, from at least 3 biological 
replicates, with error bars representing the standard error of mean (S.E.M). Mean, S.E.M, 
statistical tests, P-values and sample sizes are reported in the figure legends. 
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)$
AKT is a dominant modifier of 


.
 
Representative images showing dominant 
enhancement of the 	 eye phenotype, associated with expression of the FTD 
disease-causing 


 transgene in the 	 eye (GMR-Gal4), by AKT 
knockdown (RNAi), loss-of-function alleles (AKT
04226
 and AKT
3
) and the AKT kinase-dead 
allele (AKT
1
). * Quantification of the eye phenotype.  6  Co-expression of AKT or 
constitutively active myrAKT alleviates increased mean normalised synaptic bouton number 
() and NMJ length () at the 	 third instar larval neuromuscular junction (hemi-
segment A3, muscle 6/7) in animals pan-neuronally (nSyb-Gal4) expressing the 



 transgene. NMJ’s were analyzed across a minimum of 5 animals. One-way 
ANOVA with Dunnett’s post-hoc comparison to wild-type controls (* p <.05, *** p < .001) 
and Tukey between groups comparison (# p < .05, ## p < 0.01 and ### p < 0.001).  Reduced 
locomotor velocity observed in larvae pan-neuronally (nSyb-Gal4) expressing 

 
is ameliorated by co-expression of AKT or myrAKT. One-way ANOVA with Dunnett’s post-
hoc comparison to wild-type controls (*** p < .001) and Tukey between groups comparison 
(### p < .001).  Scale bars = 10 m. Error bars represent S.E.M, sample size is reported 
above each bar. 

)$-
AKT, a negative regulator of POSH, alleviates aberrant accumulation of POSH in the 
nervous system of 	 expressing the disease-causing 


 transgene. *
pan-neuronal (nSyb-Gal4) expression of the 


 mutant transgene results in a 
significant accumulation of mCherry-POSH positive puncta throughout the ventral nerve 
cord of third instar 	 larvae (student’s t-test *** p < .001). Aberrant accumulation 
of POSH puncta was also observed in the ventral nerve cord of flies expressing 
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

 within motor neurons (OK6-Gal4) () and in AKT kinase-dead (AKT
1
) larvae 
(student’s t-test *** p < .001) (). ) co-expression of AKT significantly reduces the 
number of POSH positive accumulations observed in the ventral nerve cord of larvae pan-
neuronally (nSyb-Gal4) expressing the 


 mutant transgene. One-way ANOVA 
with Dunnett’s post-hoc comparison to wild-type controls (*** p < .001) and Tukey between 
groups comparison (### p < .001). Scale bars = 10 m. Error bars represent S.E.M, sample 
size is reported above each bar. 
    

   
)$
POSH knockdown alleviates 


 phenotypes in 	!Knockdown of 
POSH via POSH-RNAi or using the strong hypomorphic allele POSH
74
 rescues the increased 
mean normalized synaptic bouton number (*) and mean normalized NMJ length78observed 
in larvae pan-neuornally (nSyb-Gal4) expressing the 


 mutant transgene 
(muscle 6/7, hemi-segment A3). NMJ analysis was performed across a minimum of 5 
individual animals. One-way ANOVA with Dunnett’s post-hoc comparison to wild-type 
controls (* p < .05, *** p < .001) and Tukey between groups comparison (## p < .01, ### p < 
.001). Scale bars = 10 m.  Knockdown of POSH ameliorates impaired larval locomotion in 
larvae pan-neuronally (nSyb-Gal4) expressing the 


 mutant transgene. One-way 
ANOVA with Dunnett’s post-hoc comparison to wild-type controls (* p < .05, ** p < .01, 
*** p < .001) and Tukey between groups comparison (# p < .05, ## p < .01).  pan-neuronal 
expression of the 


 mutant transgene results in a 100% pharate (pupal) lethal 
phenotype which can be ameliorated by knockdown of POSH using a homozygous POSH
74
 
hypomorphic allele (POSH
74/74
). Error bars represent S.E.M, sample size is reported above 
each bar. 

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
)$9
Aberrant neuronal accumulation of POSH is conserved in 

 
mice 
representative images and quantification, via corrected total cell fluorescence (CTCF), of 
POSH within beta 3 tubulin positive neurons in the frontal cortex of 12 month old mice 
expressing either 


 or CHMP2B
Wiltype 
under the control of the Camk2a 
promoter. d. Relative fluorescence intensity of POSH (c) was normalized against relative 
fluorescence intensity of beta 3 tubulin (b).  Student’s t-test ** p < .01, *** p < .001. n = 12, 
N = 3. Scale bars = 10 m. Error bars represent S.E.M.

)$:
POSH knockdown alleviates 


 dependent dendritic collapse in mammalian 
neurons.  Representative micrographs of mature neurons expressing FLAG-tagged 


-.) 
 or 

 
in the presence of either pSIREN-RetroQ-DsRed-
Scrambled or POSH 1+2 shRNA. Scale bars = 20m. * 


 shows significant 
reduction in cumulative branch number (compared to 

-.) 
 + Scrambled (p < 
.001) and 

 
+ POSH shRNA’s (p < .001)) (*), longest process length () 
maximum number of dendritic branches () and total arbor size () without affecting cell 
body size ().  One-way ANOVA with Dunnett’s post-hoc comparison to wild-type 
controls (*** p < .001) and Tukey between groups comparison (# p < .05, ## p < .01 and ## p 
< .001) n = 30 cells across three biological replicates. Error bars represent S.E.M, sample size 
is reported above each bar. 

)$;
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POSH knockdown alleviates aberrant apoptotic and JNK Activity in 	 and 
mammalian 


 models. Pan-neuronal (nSyb-Gal4) expression of 

 
leads to an increase in apoptotic markers in the 	 third instar larval nervous system, 
including an increase in TUNEL () and cleaved Dcp-1, the 	 effector caspase, in 
the larval ventral nerve cord (*). Neuronal expression of 


 also resulted in an 
increase in the apoptosis related 50 kDa band recognized by anti-Dcp-1 via immunoblotting 
(*). CTCF = corrected total cell fluorescence. Knockdown of POSH using the hypomorphic 
POSH
74
 allele ameliorates elevated cleaved Dcp-1 in animals expressing 

 
(*-
). One-way ANOVA with Dunnett’s post-hoc comparison to wild-type controls (*** p < 
.001) and Tukey between groups comparison (## p < .01). Immunoblot showing cleaved-
caspase 3 (CC3) in mammalian GPNT cells transfected with 

-.) 
 and 



. The deficiency locus Df(3L)H99, which ablates three critical apoptotic 
loci, reduces the 


 eye phenotype (GMR-Gal4). ) 6 	 and mouse 
models expressing 


 show elevated levels of JNK activity within the nervous 
system. Elevated JNK activity, determined using the transcriptional reporter puckered-lacZ, 
in the ventral nerve cord of 	 third instar larvae pan-neuronally expressing 



 (nSyb-Gal4) can be alleviated by POSH knockdown using the hypomorphic 
POSH
74
 allele ()). pJNK levels in cortical lysates extracted from 12 month old mice 
expressing either 


 or 

-)  
under the control of the Camk2a promoter 
() and quantified relative to the actin loading control (,  N = 3. (student’s t-test *** p < 
.001). Error bars represent S.E.M, sample size is reported above each bar.           
 
)1$
POSH is a substrate of AKT.  Immunoblot probed using the anti-phospho-(Ser/Thr) Akt 
substrate antibody following immunoprecipitation of POSH from 	 third instar 
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larval lysates. * Phos-tag mobility shift assay demonstrating a reduction in the 
phosphorylation of POSH (asterisk) in larvae pan-neuronally (nSyb-Gal4) expressing 



 and amelioration by co-expression of myrAKT.  Immunoblot showing 
POSH-shRNA knockdown efficiency in GPNT cells.  
 

	**3!
FTD: Frontotemporal Dementia 
POSH: Plenty of SH3s 
SH3RF1: SH3 Domain Containing Ring Finger 1 

5Charged Multivesicular Body Protein 2B 
JNK: Jun N-terminal Kinase 
FTLD: Frontotemporal lobar degeneration 
bvFTD: behavioral variant FTD 
FTD-MND: FTD with Motor Neuron Disease 
VCP: Valosin Containing Protein 
TBK1: TANK Binding Kinase 1 
GRN: Granulin Precursor 
RNAi: RNA interference 
shRNA: Short hairpin RNA 
()57 /	()	 *
UAS: Upstream activator sequence 
myrAKT: myristoylated AKT 
pAKT: Phospho-AKT 
NMJ: Neuromuscular Junction 
MND: Motor Neuron Disease 
Page 32 of 39Human Molecular Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 33
VNC: Ventral nerve cord 
Dcp-1: Death Caspase 1 
Puc: Puckered 
CNS: central nervous system 
AP-1: activator protein 1 
SH3RF2: SH3 Domain Containing Ring Finger 2 
HRP: horseradish peroxidase 
TUNEL: Terminal Deoxynucleotidyl Transferase (TdT)-Mediated dUTP Nick-End Labeling 
CyO: curly of oster 
GMR: Glass multimer reporter 

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